Buy Or Sell Opportunity • May 27
Now 21% overvalued Over the last 90 days, the stock has fallen 16% to €14.78. The fair value is estimated to be €12.23, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 56%. For the next 3 years, revenue is forecast to grow by 4.6% per annum. Earnings are also forecast to grow by 22% per annum over the same time period. Declared Dividend • Apr 01
Dividend increased to €0.60 Dividend of €0.60 is 20% higher than last year. Ex-date: 20th July 2026 Payment date: 22nd July 2026 Dividend yield will be 3.6%, which is higher than the industry average of 0.9%. Sustainability & Growth Dividend is not adequately covered by earnings (91% earnings payout ratio) and the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 5.8% per year over the past 9 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 1.3% to bring the payout ratio under control. However, EPS is expected to remain steady over the next 2 years, which means the dividend may need to be reduced to reach a sustainable payout ratio. Reported Earnings • Mar 31
Full year 2025 earnings released Full year 2025 results: Revenue: €546.2m (up 7.1% from FY 2024). Net income: €16.2m (up 6.4% from FY 2024). Profit margin: 3.0% (in line with FY 2024). Revenue is forecast to grow 5.4% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Healthcare Services industry in Europe. Tillkännagivande • Mar 31
GPI S.p.A. announces Annual dividend, payable on July 22, 2026 GPI S.p.A. announced Annual dividend of EUR 0.6000 per share payable on July 22, 2026, ex-date on July 20, 2026 and record date on July 21, 2026. Valuation Update With 7 Day Price Move • Nov 17
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to €14.82, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 16x in the Healthcare Services industry in Europe. Total returns to shareholders of 28% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €7.86 per share. New Risk • Nov 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.1x net interest cover). Dividend is not well covered by earnings and cash flows. Payout ratio: 91% Dividend per share is over 21x cash flows per share. Minor Risk Share price has been volatile over the past 3 months (5.9% average weekly change). Price Target Changed • Oct 14
Price target increased by 11% to €18.57 Up from €16.67, the current price target is an average from 3 analysts. New target price is approximately in line with last closing price of €17.84. Stock is up 44% over the past year. The company is forecast to post earnings per share of €0.77 for next year compared to €0.53 last year. New Risk • Aug 31
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.5x net interest cover). Dividend is not well covered by earnings and cash flows. Payout ratio: 95% Paying a dividend despite having no free cash flows. Minor Risk Share price has been volatile over the past 3 months (5.3% average weekly change). Tillkännagivande • Jul 17
KKR Reportedly Mulls Acquisition of GPI KKR & Co. Inc. (NYSE:KKR), the buyout firm that’s been scouting for takeover targets amid the recent market volatility, is considering a potential acquisition of Italian health-care technology firm GPI S.p.A. (BIT:GPI), according to people with knowledge of the matter. The US private equity firm has been speaking with advisers in recent weeks as it considers a potential deal to take Trent-based GPI private, the people said, asking not to be identified as the matter is private. The stock is up about 27% in Milan trading this year, giving the company a market value of about €385 million ($446 million). An investment vehicle backed by GPI Chief Executive Officer Fausto Manzana is the company’s biggest shareholder, with a 48% stake that’s equivalent to 57% of the voting rights, according to its annual report. Deliberations are ongoing, though there’s no certainty they will lead to a transaction, the people said. A representative for KKR declined to comment. A spokesperson for GPI didn’t comment. Upcoming Dividend • Jul 14
Upcoming dividend of €0.50 per share Eligible shareholders must have bought the stock before 21 July 2025. Payment date: 23 July 2025. Payout ratio is on the higher end at 95% but the company is not cash flow positive. Trailing yield: 3.8%. Lower than top quartile of Italian dividend payers (5.1%). Higher than average of industry peers (1.1%). Tillkännagivande • Jul 08
GPI S.p.A. to Report First Half, 2025 Results on Sep 29, 2025 GPI S.p.A. announced that they will report first half, 2025 results on Sep 29, 2025 Tillkännagivande • Jul 02
GPI S.p.A. (BIT:GPI) acquired remaining 35% stake in Tesi Elettronica E Sistemi Informativi S.P.A. for €27.8 million. GPI S.p.A. (BIT:GPI) acquired remaining 35% stake in Tesi Elettronica E Sistemi Informativi S.P.A. for €27.8 million on June 30, 2025. The price for acquiring the remaining shares, which represent 35% of TESI's share capital, is €27.8 million i.e, Payment for the acquisition of a 35% stake in TESI was made using the following methods: (i) a €5 million deposit upon signing, of which €4 million in cash and €1 million via the transfer of Gpi; (ii) the amount of €15.9 million in cash paid at the closing, which took place today, 30 June 2025; (iii) the difference settled through the assumption and offsetting of the sellers’ payables to companies within the Tesi group.
GPI S.p.A. (BIT:GPI) completed the acquisition of remaining 35% stake in Tesi Elettronica E Sistemi Informativi S.P.A. on June 30, 2025. Major Estimate Revision • Apr 16
Consensus EPS estimates fall by 20% The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate fell from €0.98 to €0.783 per share. Revenue forecast steady at €534.8m. Net income forecast to grow 49% next year vs 42% growth forecast for Healthcare Services industry in Italy. Consensus price target of €16.67 unchanged from last update. Share price rose 7.7% to €8.66 over the past week. Major Estimate Revision • Apr 04
Consensus EPS estimates increase by 31% The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate increased from €0.748 to €0.98. Revenue forecast steady at €530.9m. Net income forecast to grow 82% next year vs 36% growth forecast for Healthcare Services industry in Italy. Consensus price target of €16.67 unchanged from last update. Share price fell 8.8% to €8.30 over the past week. Tillkännagivande • Apr 02
GPI S.p.A. announces Annual dividend, payable on July 23, 2025 GPI S.p.A. announced Annual dividend of EUR 0.5000 per share payable on July 23, 2025, ex-date on July 21, 2025 and record date on July 22, 2025. Reported Earnings • Mar 30
Full year 2024 earnings released Full year 2024 results: Revenue: €509.9m (up 18% from FY 2023). Net income: €15.2m (up 485% from FY 2023). Profit margin: 3.0% (up from 0.6% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.2% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe. Tillkännagivande • Mar 20
GPI S.p.A., Annual General Meeting, Apr 29, 2025 GPI S.p.A., Annual General Meeting, Apr 29, 2025, at 11:00 W. Europe Standard Time. Buy Or Sell Opportunity • Jan 14
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 18% to €10.16. The fair value is estimated to be €12.76, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has declined by 54%. Revenue is forecast to grow by 12% in 2 years. Earnings are forecast to grow by 143% in the next 2 years. Buy Or Sell Opportunity • Dec 27
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 20% to €10.08. The fair value is estimated to be €12.63, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has declined by 54%. Revenue is forecast to grow by 12% in 2 years. Earnings are forecast to grow by 143% in the next 2 years. Upcoming Dividend • Dec 02
Upcoming dividend of €0.35 per share Eligible shareholders must have bought the stock before 09 December 2024. Payment date: 11 December 2024. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 4.5%. Lower than top quartile of Italian dividend payers (5.6%). Higher than average of industry peers (2.6%). Buy Or Sell Opportunity • Oct 03
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 1.8% to €12.74. The fair value is estimated to be €10.60, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue is forecast to grow by 10% in 2 years. Earnings are forecast to grow by 187% in the next 2 years. Reported Earnings • Oct 02
First half 2024 earnings released First half 2024 results: Revenue: €236.4m (up 23% from 1H 2023). Net income: €3.08m (up 439% from 1H 2023). Profit margin: 1.3% (up from 0.3% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe. Buy Or Sell Opportunity • Sep 09
Now 24% overvalued after recent price rise Over the last 90 days, the stock has risen 1.2% to €12.28. The fair value is estimated to be €9.94, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has declined by 46%. For the next 3 years, revenue is forecast to grow by 7.3% per annum. Earnings are also forecast to grow by 47% per annum over the same time period. Buy Or Sell Opportunity • Aug 08
Now 20% overvalued Over the last 90 days, the stock has fallen 5.8% to €11.98. The fair value is estimated to be €9.94, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has declined by 46%. For the next 3 years, revenue is forecast to grow by 7.3% per annum. Earnings are also forecast to grow by 47% per annum over the same time period. Upcoming Dividend • May 20
Upcoming dividend of €0.50 per share Eligible shareholders must have bought the stock before 27 May 2024. Payment date: 29 May 2024. The company is paying out more than 100% of its profits and is cash flow negative. Trailing yield: 3.8%. Lower than top quartile of Italian dividend payers (5.3%). Higher than average of industry peers (1.6%). Price Target Changed • Apr 17
Price target increased by 7.2% to €16.30 Up from €15.20, the current price target is an average from 3 analysts. New target price is 30% above last closing price of €12.50. Stock is up 0.2% over the past year. The company is forecast to post earnings per share of €0.58 for next year compared to €0.09 last year. Major Estimate Revision • Apr 04
Consensus EPS estimates fall by 41%, revenue upgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast increased from €483.8m to €500.8m. EPS estimate fell from €0.973 to €0.57 per share. Net income forecast to grow 516% next year vs 47% growth forecast for Healthcare Services industry in Italy. Consensus price target up from €15.20 to €15.53. Share price was steady at €11.92 over the past week. Reported Earnings • Mar 31
Full year 2023 earnings released Full year 2023 results: Revenue: €433.4m (up 20% from FY 2022). Net income: €2.60m (down 74% from FY 2022). Profit margin: 0.6% (down from 2.8% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.1% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe. Tillkännagivande • Mar 21
Zucchetti Hospitality S.R.L. completed the acquisition of Argentea S.r.l. from GPI S.p.A. (BIT:GPI). Zucchetti Hospitality S.R.L. signed an agreement to acquire Argentea S.r.l. from GPI S.p.A. (BIT:GPI) for approximately €105 million on March 15, 2024. The consideration for the sale of 100% of Argentea S.r.l., to be paid in full in cash at closing, has been agreed upon at approximately €99 million, based on an equity value of Argentea S.r.l. of approximately €105 million. An earn-out clause is also provided for, whereby the buyer undertakes to pay Gpi S.p.A. an additional amount of €6 million, on the sole condition that Argentea S.r.l.'s FY 2024 EBITDA, to be calculated in continuity with previous management criteria, is at least equal to that of FY 2023. In FY 2023, Argentea S.r.l. reported production value of €16.3 million and EBITDA of €6.9 million. This transaction is expected to be completed by end of March 2024. Intermonte acted as financial advisor to Zucchetti Hospitality S.R.L. Equita acted as financial advisor, EY-Parthenon as industrial advisor and Studio Legale Pavia e Ansaldo acted as legal advisor to GPI S.p.A. (BIT:GPI). Zucchetti Hospitality S.R.L. completed the acquisition of Argentea S.r.l. from GPI S.p.A. (BIT:GPI) on March 20, 2024. Valuation Update With 7 Day Price Move • Feb 17
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €10.86, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 16x in the Healthcare Services industry in Europe. Total returns to shareholders of 30% over the past three years. Valuation Update With 7 Day Price Move • Feb 17
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €10.86, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 16x in the Healthcare Services industry in Europe. Total returns to shareholders of 30% over the past three years. Price Target Changed • Oct 20
Price target decreased by 9.3% to €15.20 Down from €16.77, the current price target is an average from 3 analysts. New target price is 87% above last closing price of €8.14. Stock is down 31% over the past year. The company is forecast to post earnings per share of €0.78 for next year compared to €0.35 last year. Major Estimate Revision • Oct 01
Consensus EPS estimates increase by 25% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from €418.4m to €426.1m. EPS estimate increased from €0.635 to €0.791 per share. Net income forecast to grow 81% next year vs 28% growth forecast for Healthcare Services industry in Italy. Consensus price target of €16.83 unchanged from last update. Share price fell 3.6% to €8.95 over the past week. Upcoming Dividend • May 08
Upcoming dividend of €0.50 per share at 4.2% yield Eligible shareholders must have bought the stock before 15 May 2023. Payment date: 17 May 2023. Payout ratio is on the higher end at 85% but the company is not cash flow positive. Trailing yield: 4.2%. Lower than top quartile of Italian dividend payers (5.2%). Higher than average of industry peers (1.3%). Major Estimate Revision • Apr 18
Consensus EPS estimates fall by 15% The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate fell from €0.59 to €0.50. Revenue forecast unchanged from €420.5m at last update. Net income forecast to grow 47% next year vs 30% growth forecast for Healthcare Services industry in Italy. Consensus price target of €17.43 unchanged from last update. Share price fell 2.3% to €12.50 over the past week. Major Estimate Revision • Mar 31
Consensus EPS estimates fall by 40%, revenue upgraded The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from €409.2m to €420.5m. EPS estimate fell from €0.981 to €0.59 per share. Net income forecast to grow 36% next year vs 30% growth forecast for Healthcare Services industry in Italy. Consensus price target broadly unchanged at €17.43. Share price fell 2.7% to €12.80 over the past week. Major Estimate Revision • Feb 19
Consensus EPS estimates fall by 16% The consensus outlook for fiscal year 2022 has been updated. 2022 EPS estimate fell from €0.668 to €0.558 per share. Revenue forecast steady at €355.7m. Net income forecast to grow 37% next year vs 29% growth forecast for Healthcare Services industry in Italy. Consensus price target down from €18.03 to €17.63. Share price fell 3.8% to €13.76 over the past week. Major Estimate Revision • Dec 26
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 EPS estimate fell from €0.85 to €0.65 per share. Revenue forecast steady at €354.8m. Net income forecast to grow 46% next year vs 39% growth forecast for Healthcare Services industry in Italy. Consensus price target broadly unchanged at €18.03. Share price was steady at €13.64 over the past week. Major Estimate Revision • Dec 08
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 EPS estimate fell from €1.01 to €0.85 per share. Revenue forecast steady at €354.0m. Net income forecast to grow 47% next year vs 39% growth forecast for Healthcare Services industry in Italy. Consensus price target of €17.97 unchanged from last update. Share price was steady at €13.36 over the past week. Tillkännagivande • Nov 23
GPI S.p.A. acquired 65% stake in Tesi Elettronica E Sistemi Informativi S.P.A. from Tesi Group, Sorean S.r.l., Aef Luxor Group SL and Magica S.R.L. for Tesi Elettronica E Sistemi Informativi S.P.A. for €58.5 million. GPI (GPI:IM) signed the letter of intent to acquire 75% stake in Tesi Elettronica E Sistemi Informativi S.P.A. from Tesi Group, Sorean S.r.l., Aef Luxor Group SL and Magica S.R.L. on January 4, 2022. On May 23, 2022, GPI S.p.A. signed an agreement to acquire a 65% stake in Tesi Elettronica E Sistemi Informativi S.P.A. from Tesi Group, Sorean S.r.l., Aef Luxor Group SL and Magica S.R.L. for Tesi Elettronica E Sistemi Informativi S.P.A. for €58.5 million. The consideration will be settled in the following ways: a deposit of €8 million at signing; €28.3 million to be paid at the closing, the remaining portion, equal to €22.2 million, by January 31, 2023. Completion of the transaction is subject to the approval of the competent bodies, as well as to any authorizations necessary from the antitrust authorities. The transaction is expected to complete by September 30, 2022. On May 23, 2022, GPI S.p.A. agreed with the selling parties to extend the closing date to November, 29 2022.
GPI S.p.A. completed the acquisition of 65% stake in Tesi Elettronica E Sistemi Informativi S.P.A. from Tesi Group, Sorean S.r.l., Aef Luxor Group SL and Magica S.R.L. for Tesi Elettronica E Sistemi Informativi S.P.A. for €58.5 million on November 21, 2022. The consideration of €28.3 million paid at the closing was funded using a combination of available liquidity and short-term bank loans. Studio Baldi & Partners acted as legal advisor, Intermonte SIM S.p.A. acted as financial advisor to GPI S.p.A. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 6 non-independent directors. Independent Director Michele Andreaus was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Sep 18
First half 2022 earnings released First half 2022 results: Revenue: €168.9m (up 11% from 1H 2021). Net income: €331.0k (up €359.0k from 1H 2021). Profit margin: 0.2% (up from 0% in 1H 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 10.0% growth forecast for the Healthcare Services industry in Europe. Price Target Changed • Aug 17
Price target decreased to €16.10 Down from €18.50, the current price target is an average from 2 analysts. New target price is 15% above last closing price of €14.02. Stock is up 12% over the past year. The company is forecast to post earnings per share of €0.90 for next year compared to €0.61 last year. Upcoming Dividend • May 09
Upcoming dividend of €0.50 per share Eligible shareholders must have bought the stock before 16 May 2022. Payment date: 18 May 2022. Payout ratio is on the higher end at 82% but the company is not cash flow positive. Trailing yield: 3.8%. Lower than top quartile of Italian dividend payers (4.8%). Higher than average of industry peers (1.4%). Board Change • Apr 27
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 7 experienced directors. 4 highly experienced directors. 4 independent directors (6 non-independent directors). Independent Director Michele Andreaus was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Buying Opportunity • Mar 31
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 14%. The fair value is estimated to be €17.74, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 14%. Revenue is forecast to grow by 14% in 2 years. Earnings is forecast to grow by 42% in the next 2 years. Price Target Changed • Jan 06
Price target increased to €18.50 Up from €17.07, the current price target is an average from 3 analysts. New target price is 10% above last closing price of €16.75. Stock is up 113% over the past year. The company is forecast to post earnings per share of €0.79 for next year compared to €0.75 last year. Tillkännagivande • Jan 06
GPI (GPI:IM) signed the letter of intent to acquire 75% stake in Tesi Elettronica E Sistemi Informativi S.P.A. from Tesi Group, Sorean S.r.l., Aef Luxor Group SL and Magica S.R.L. GPI (GPI:IM) signed the letter of intent to acquire 75% stake in Tesi Elettronica E Sistemi Informativi S.P.A. from Tesi Group, Sorean S.r.l., Aef Luxor Group SL and Magica S.R.L. on January 4, 2022.The letter of intent, guaranteed by an exclusivity clause until 28 February 2022, provides for the signing of the binding agreement by 28 February 2022 and for the closing, indicatively by 30 April 2022, subject to the positive and satisfactory outcome of the due diligence carried out by GPI. Completion of the transaction is subject to the approval of the competent bodies, as well as to any authorizations necessary from the antitrust authorities. Price Target Changed • Nov 27
Price target increased to €18.17 Up from €16.73, the current price target is an average from 3 analysts. New target price is 42% above last closing price of €12.80. Stock is up 79% over the past year. The company is forecast to post earnings per share of €0.83 for next year compared to €0.75 last year. Price Target Changed • Jul 27
Price target increased to €16.23 Up from €14.63, the current price target is an average from 3 analysts. New target price is 21% above last closing price of €13.45. Stock is up 94% over the past year. Upcoming Dividend • Jul 19
Upcoming dividend of €0.50 per share Eligible shareholders must have bought the stock before 26 July 2021. Payment date: 28 July 2021. Trailing yield: 3.6%. Lower than top quartile of Italian dividend payers (3.8%). Higher than average of industry peers (1.0%). Major Estimate Revision • Feb 12
Analysts increase EPS estimates to €0.64 The 2020 consensus revenue estimate increased from €256.6m to €264.4m. The earnings per share estimate also received an upgrade from €0.52 to €0.64 for the same period. Net income is expected to shrink by 2.7% next year compared to 29% growth forecast for the Healthcare Services industry in Italy . The consensus price target increased from €10.50 to €10.85. Share price is up 8.1% to €9.08 over the past week. Is New 90 Day High Low • Feb 05
New 90-day high: €8.40 The company is up 26% from its price of €6.66 on 06 November 2020. The Italian market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.42 per share. Tillkännagivande • Jan 24
GPI SpA (BIT:GPI) acquired remaining 40% stake in Hemasoft Software S.L for €5.7 million. GPI SpA (BIT:GPI) acquired the remaining 40% stake in Hemasoft Software S.L for €5.7 million on January 22, 2021.
GPI SpA (BIT:GPI) completed the acquisition of the remaining 40% stake in Hemasoft Software S.L for on January 22, 2021. Tillkännagivande • Jan 06
GPI SpA (BIT:GPI) completed the acquisition of MEDINFO GROUP. GPI SpA (BIT:GPI) signed an agreement to acquire MEDINFO GROUP for €9 million on May 25, 2020. The purchase price will be paid at closing with a price adjustment mechanism up to €3 million. The acquisition will be financed by means of part of the mini bond issued on December 20, 2019. In 2019, MEDINFO GROUP reported revenue of €3.9 million and an EBITDA of approximately €1.3 million. The transaction is expected to complete by September 30, 2020.
GPI SpA (BIT:GPI) completed the acquisition of MEDINFO GROUP on January 4, 2021. The consideration paid is €10.4 million and additional €1.2 million calculated according to the adjustment mechanism agreed between the parties, to be paid according to the results of the years 2020 and 2021. Is New 90 Day High Low • Jan 05
New 90-day high: €7.74 The company is up 15% from its price of €6.74 on 07 October 2020. The Italian market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €8.57 per share. Is New 90 Day High Low • Dec 10
New 90-day high: €7.52 The company is up 13% from its price of €6.68 on 10 September 2020. The Italian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €7.01 per share. Is New 90 Day High Low • Nov 19
New 90-day high: €7.10 The company is up 7.0% from its price of €6.66 on 21 August 2020. The Italian market is also up 7.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Healthcare Services industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €6.64 per share. Is New 90 Day High Low • Oct 29
New 90-day low: €6.42 The company is down 3.0% from its price of €6.64 on 30 July 2020. The Italian market is down 8.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Healthcare Services industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €6.46 per share. Reported Earnings • Oct 03
First half earnings released Over the last 12 months the company has reported total profits of €8.28m, down 4.5% from the prior year. Total revenue was €247.7m over the last 12 months, up 12% from the prior year. Tillkännagivande • Sep 08
GPI SpA announced that it expects to receive €4.5 million in funding GPI SpA (BIT:GPI) announced a private placement of 3.5% 2019-2025 non-convertible bond notes for gross proceeds of €4.5 million on September 4, 2020. The notes bear a fixed coupon rate of 3.5% per annum and will mature in 2025. Tillkännagivande • Aug 01
GPI SpA (BIT:GPI) acquired the remaining 30% stake in BIM Italia Srl for €5.1 million. GPI SpA (BIT:GPI) acquired the remaining 30% stake in BIM Italia Srl for €5.1 million on July 31, 2020. The transaction was supported with a loan from Sparkasse Cassa di Risparmio di Bolzano. Post completion of the transaction, GPI SpA now owns the entire 100% stake in BIM Italia Srl.
GPI SpA (BIT:GPI) completed the acquisition of the remaining 30% stake in BIM Italia Srl on July 31, 2020. Tillkännagivande • Jul 31
GPI SpA (BIT:GPI) completed the acquisition of Intelligence Systems Business Unit from Oslo Srl. GPI SpA (BIT:GPI) signed an agreement to acquire Intelligence Systems Business Unit from Oslo Srl for €5.6 million on January 16, 2020. As per terms, a new company will be set up from Intelligence Systems Business Unit of Oslo Srl in which GPI SpA will acquire 65% stake for €5.6 million plus earn-out. the consideration shall be paid with resources from bond and in kind. The remaining 35% stake shall be acquired through put & call options.
GPI SpA (BIT:GPI) completed the acquisition of Intelligence Systems Business Unit from Oslo Srl on April 10, 2020. 
